<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33436549</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-4889</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell death &amp; disease</Title>
          <ISOAbbreviation>Cell Death Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The role of the Hippo pathway in the pathogenesis of inflammatory bowel disease.</ArticleTitle>
        <Pagination>
          <StartPage>79</StartPage>
          <MedlinePgn>79</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">79</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-021-03395-3</ELocationID>
        <Abstract>
          <AbstractText>Inflammatory bowel disease (IBD) is a chronic and recurrent inflammatory disorder that primarily comprises Crohn's disease (CD) and ulcerative colitis (UC). Owing to its increasing prevalence in Eastern countries and the intractable challenges faced during IBD treatment, extensive research on IBD has been carried out over the last few years. Although the precise aetiology of IBD is undefined, the currently accepted hypothesis for IBD pathogenesis considers it to be a combination of environment, genetic predisposition, gut microbiota, and abnormal immunity. A recently emerged signalling pathway, the Hippo pathway, acts as a key regulator of cell growth, tissue homoeostasis, organ size, and has been implicated in several human cancers. In the past few years, studies have revealed the importance of the Hippo pathway in gastrointestinal tract physiology and gastrointestinal diseases, such as colorectal cancer and IBD. However, the role of the Hippo pathway and its exact impact in IBD remains to be elucidated. This review summarises the latest scientific literature on the involvement of this pathway in IBD from the following perspectives that account for the IBD pathogenesis: intestinal epithelial cell regeneration, immune regulation, gut microbiota, and angiogenesis. A comprehensive understanding of the specific role of the Hippo pathway in IBD will provide novel insights into future research directions and clinical implications of the Hippo pathway.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Zhuo</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0002-0976-079X</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Guang</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Liguo</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Shenghong</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China. zhshh3@mail.sysu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>01</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cell Death Dis</MedlineTA>
        <NlmUniqueID>101524092</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000090683" MajorTopicYN="N">Hippo Signaling Pathway</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015212" MajorTopicYN="N">Inflammatory Bowel Diseases</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that they have no conflict of interest</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33436549</ArticleId>
        <ArticleId IdType="pmc">PMC7804279</ArticleId>
        <ArticleId IdType="doi">10.1038/s41419-021-03395-3</ArticleId>
        <ArticleId IdType="pii">10.1038/s41419-021-03395-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427–434. doi: 10.1038/nature06005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature06005</ArticleId>
            <ArticleId IdType="pubmed">17653185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 2015;12:720–727. doi: 10.1038/nrgastro.2015.150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrgastro.2015.150</ArticleId>
            <ArticleId IdType="pubmed">26323879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma S, Meng Z, Chen R, Guan KL. The Hippo pathway: biology and pathophysiology. Annu. Rev. Biochem. 2019;88:577–604. doi: 10.1146/annurev-biochem-013118-111829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-biochem-013118-111829</ArticleId>
            <ArticleId IdType="pubmed">30566373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng Z, Moroishi T, Guan KL. Mechanisms of Hippo pathway regulation. Genes Dev. 2016;30:1–17. doi: 10.1101/gad.274027.115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.274027.115</ArticleId>
            <ArticleId IdType="pmc">PMC4701972</ArticleId>
            <ArticleId IdType="pubmed">26728553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, et al.  NDR functions as a physiological YAP1 kinase in the intestinal epithelium. Curr. Biol. 2015;25:296–305. doi: 10.1016/j.cub.2014.11.054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2014.11.054</ArticleId>
            <ArticleId IdType="pmc">PMC4426889</ArticleId>
            <ArticleId IdType="pubmed">25601544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharif AAD, Hergovich A. The NDR/LATS protein kinases in immunology and cancer biology. Semin. Cancer Biol. 2018;48:104–114. doi: 10.1016/j.semcancer.2017.04.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2017.04.010</ArticleId>
            <ArticleId IdType="pubmed">28579171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng Z, et al.  MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. Nat. Commun. 2015;6:8357. doi: 10.1038/ncomms9357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms9357</ArticleId>
            <ArticleId IdType="pmc">PMC4600732</ArticleId>
            <ArticleId IdType="pubmed">26437443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai J, et al.  The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. 2010;24:2383–2388. doi: 10.1101/gad.1978810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1978810</ArticleId>
            <ArticleId IdType="pmc">PMC2964748</ArticleId>
            <ArticleId IdType="pubmed">21041407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taniguchi K, et al.  A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015;519:57–62. doi: 10.1038/nature14228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14228</ArticleId>
            <ArticleId IdType="pmc">PMC4447318</ArticleId>
            <ArticleId IdType="pubmed">25731159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan EH, et al.  The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene. 2005;24:2076–2086. doi: 10.1038/sj.onc.1208445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1208445</ArticleId>
            <ArticleId IdType="pubmed">15688006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arranz A, et al.  Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. Proc. Natl Acad. Sci. USA. 2012;109:9517–9522. doi: 10.1073/pnas.1119038109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1119038109</ArticleId>
            <ArticleId IdType="pmc">PMC3386059</ArticleId>
            <ArticleId IdType="pubmed">22647600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nterma P, Panopoulou E, Papadaki-Petrou E, Assimakopoulou M. Immunohistochemical profile of tumor suppressor proteins RASSF1A and LATS1/2 in relation to p73 and YAP expression, of human inflammatory bowel disease and normal intestine. Pathol. Oncol. Res. 2020;26:567–574. doi: 10.1007/s12253-018-00575-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12253-018-00575-z</ArticleId>
            <ArticleId IdType="pubmed">30604274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai ZC, et al.  Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. Cell. 2005;120:675–685. doi: 10.1016/j.cell.2004.12.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2004.12.036</ArticleId>
            <ArticleId IdType="pubmed">15766530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hergovich A. The roles of NDR protein kinases in Hippo signalling. Genes (Basel) 2016;7:21. doi: 10.3390/genes7050021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/genes7050021</ArticleId>
            <ArticleId IdType="pmc">PMC4880841</ArticleId>
            <ArticleId IdType="pubmed">27213455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S, et al.  The crosstalk between Hippo-YAP pathway and innate immunity. Front. Immunol. 2020;11:323. doi: 10.3389/fimmu.2020.00323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.00323</ArticleId>
            <ArticleId IdType="pmc">PMC7056731</ArticleId>
            <ArticleId IdType="pubmed">32174922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hong W, Guan KL. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin. Cell Dev. Biol. 2012;23:785–793. doi: 10.1016/j.semcdb.2012.05.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcdb.2012.05.004</ArticleId>
            <ArticleId IdType="pmc">PMC3459069</ArticleId>
            <ArticleId IdType="pubmed">22659496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lei QY, et al.  TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol. Cell Biol. 2008;28:2426–2436. doi: 10.1128/MCB.01874-07.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.01874-07</ArticleId>
            <ArticleId IdType="pmc">PMC2268418</ArticleId>
            <ArticleId IdType="pubmed">18227151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hong AW, Meng Z, Guan KL. The Hippo pathway in intestinal regeneration and disease. Nat. Rev. Gastroenterol. Hepatol. 2016;13:324–337. doi: 10.1038/nrgastro.2016.59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrgastro.2016.59</ArticleId>
            <ArticleId IdType="pmc">PMC5642988</ArticleId>
            <ArticleId IdType="pubmed">27147489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B, et al.  TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22:1962–1971. doi: 10.1101/gad.1664408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1664408</ArticleId>
            <ArticleId IdType="pmc">PMC2492741</ArticleId>
            <ArticleId IdType="pubmed">18579750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, et al.  TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J. Biol. Chem. 2009;284:13355–13362. doi: 10.1074/jbc.M900843200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M900843200</ArticleId>
            <ArticleId IdType="pmc">PMC2679435</ArticleId>
            <ArticleId IdType="pubmed">19324877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan D. The hippo signaling pathway in development and cancer. Dev. Cell. 2010;19:491–505. doi: 10.1016/j.devcel.2010.09.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2010.09.011</ArticleId>
            <ArticleId IdType="pmc">PMC3124840</ArticleId>
            <ArticleId IdType="pubmed">20951342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen YA, et al.  WW domain-containing proteins YAP and TAZ in the Hippo pathway as key regulators in stemness maintenance, tissue homeostasis, and tumorigenesis. Front. Oncol. 2019;9:60. doi: 10.3389/fonc.2019.00060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2019.00060</ArticleId>
            <ArticleId IdType="pmc">PMC6378284</ArticleId>
            <ArticleId IdType="pubmed">30805310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat. Rev. Cancer. 2013;13:246–257. doi: 10.1038/nrc3458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3458</ArticleId>
            <ArticleId IdType="pubmed">23467301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boggiano JC, Vanderzalm PJ, Fehon RG. Tao-1 phosphorylates Hippo/MST kinases to regulate the Hippo-Salvador-Warts tumor suppressor pathway. Dev. Cell. 2011;21:888–895. doi: 10.1016/j.devcel.2011.08.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2011.08.028</ArticleId>
            <ArticleId IdType="pmc">PMC3217187</ArticleId>
            <ArticleId IdType="pubmed">22075147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poon CL, Lin JI, Zhang X, Harvey KF. The sterile 20-like kinase Tao-1 controls tissue growth by regulating the Salvador-Warts-Hippo pathway. Dev. Cell. 2011;21:896–906. doi: 10.1016/j.devcel.2011.09.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2011.09.012</ArticleId>
            <ArticleId IdType="pubmed">22075148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vichalkovski A, et al.  NDR kinase is activated by RASSF1A/MST1 in response to Fas receptor stimulation and promotes apoptosis. Curr. Biol. 2008;18:1889–1895. doi: 10.1016/j.cub.2008.10.060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2008.10.060</ArticleId>
            <ArticleId IdType="pubmed">19062280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh HJ, et al.  Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res. 2006;66:2562–2569. doi: 10.1158/0008-5472.CAN-05-2951.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-2951</ArticleId>
            <ArticleId IdType="pubmed">16510573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matallanas D, et al.  RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol. Cell. 2007;27:962–975. doi: 10.1016/j.molcel.2007.08.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2007.08.008</ArticleId>
            <ArticleId IdType="pmc">PMC2821687</ArticleId>
            <ArticleId IdType="pubmed">17889669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu FX, et al.  Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012;150:780–791. doi: 10.1016/j.cell.2012.06.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.06.037</ArticleId>
            <ArticleId IdType="pmc">PMC3433174</ArticleId>
            <ArticleId IdType="pubmed">22863277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng Y, et al.  Identification of Happyhour/MAP4K as alternative Hpo/Mst-like kinases in the Hippo kinase cascade. Dev. Cell. 2015;34:642–655. doi: 10.1016/j.devcel.2015.08.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2015.08.014</ArticleId>
            <ArticleId IdType="pmc">PMC4589524</ArticleId>
            <ArticleId IdType="pubmed">26364751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Bouteiller M, Jensen KB. Hippo signalling directs intestinal fate. Nat. Cell Biol. 2015;17:5–6. doi: 10.1038/ncb3086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3086</ArticleId>
            <ArticleId IdType="pubmed">25679030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramos A, Camargo FD. The Hippo signaling pathway and stem cell biology. Trends Cell Biol. 2012;22:339–346. doi: 10.1016/j.tcb.2012.04.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2012.04.006</ArticleId>
            <ArticleId IdType="pmc">PMC3383919</ArticleId>
            <ArticleId IdType="pubmed">22658639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat. Cell Biol. 2011;13:877–883. doi: 10.1038/ncb2303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb2303</ArticleId>
            <ArticleId IdType="pmc">PMC3987945</ArticleId>
            <ArticleId IdType="pubmed">21808241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015;163:811–828. doi: 10.1016/j.cell.2015.10.044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2015.10.044</ArticleId>
            <ArticleId IdType="pmc">PMC4638384</ArticleId>
            <ArticleId IdType="pubmed">26544935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu FX, Meng Z, Plouffe SW, Guan KL. Hippo pathway regulation of gastrointestinal tissues. Annu. Rev. Physiol. 2015;77:201–227. doi: 10.1146/annurev-physiol-021014-071733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-physiol-021014-071733</ArticleId>
            <ArticleId IdType="pubmed">25293527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong J, et al.  Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130:1120–1133. doi: 10.1016/j.cell.2007.07.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2007.07.019</ArticleId>
            <ArticleId IdType="pmc">PMC2666353</ArticleId>
            <ArticleId IdType="pubmed">17889654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell. 2005;122:421–434. doi: 10.1016/j.cell.2005.06.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2005.06.007</ArticleId>
            <ArticleId IdType="pubmed">16096061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo T, et al.  A novel partner of Scalloped regulates Hippo signaling via antagonizing Scalloped-Yorkie activity. Cell Res. 2013;23:1201–1214. doi: 10.1038/cr.2013.120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cr.2013.120</ArticleId>
            <ArticleId IdType="pmc">PMC3790236</ArticleId>
            <ArticleId IdType="pubmed">23999857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B, et al.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21:2747–2761. doi: 10.1101/gad.1602907.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1602907</ArticleId>
            <ArticleId IdType="pmc">PMC2045129</ArticleId>
            <ArticleId IdType="pubmed">17974916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moroishi T, et al.  A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis. Genes Dev. 2015;29:1271–1284. doi: 10.1101/gad.262816.115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.262816.115</ArticleId>
            <ArticleId IdType="pmc">PMC4495398</ArticleId>
            <ArticleId IdType="pubmed">26109050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kodaka M, Hata Y. The mammalian Hippo pathway: regulation and function of YAP1 and TAZ. Cell Mol. Life Sci. 2015;72:285–306. doi: 10.1007/s00018-014-1742-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-014-1742-9</ArticleId>
            <ArticleId IdType="pubmed">25266986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol. Rev. 2014;94:1287–1312. doi: 10.1152/physrev.00005.2014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/physrev.00005.2014</ArticleId>
            <ArticleId IdType="pubmed">25287865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng F, et al.  YAP triggers the Wnt/β-catenin signalling pathway and promotes enterocyte self-renewal, regeneration and tumorigenesis after DSS-induced injury. Cell Death Dis. 2018;9:153. doi: 10.1038/s41419-017-0244-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-017-0244-8</ArticleId>
            <ArticleId IdType="pmc">PMC5833613</ArticleId>
            <ArticleId IdType="pubmed">29396428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou D, et al.  Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc. Natl Acad. Sci. USA. 2011;108:E1312–E1320. doi: 10.1073/pnas.1110428108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1110428108</ArticleId>
            <ArticleId IdType="pmc">PMC3241824</ArticleId>
            <ArticleId IdType="pubmed">22042863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye S, et al.  YAP1-mediated suppression of USP31 enhances NFκB activity to promote sarcomagenesis. Cancer Res. 2018;78:2705–2720. doi: 10.1158/0008-5472.CAN-17-4052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-4052</ArticleId>
            <ArticleId IdType="pmc">PMC6314302</ArticleId>
            <ArticleId IdType="pubmed">29490948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee IY, et al.  MST1 negatively regulates TNFα-induced NF-κB signaling through modulating LUBAC activity. Mol. Cell. 2019;73:1138–1149.e1136. doi: 10.1016/j.molcel.2019.01.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2019.01.022</ArticleId>
            <ArticleId IdType="pubmed">30901564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu M, et al.  MicroRNA-590-5p inhibits intestinal inflammation by targeting YAP. J. Crohns Colitis. 2018;12:993–1004. doi: 10.1093/ecco-jcc/jjy046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjy046</ArticleId>
            <ArticleId IdType="pubmed">29912317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Itoh K, Brott BK, Bae GU, Ratcliffe MJ, Sokol SY. Nuclear localization is required for Dishevelled function in Wnt/beta-catenin signaling. J. Biol. 2005;4:3. doi: 10.1186/jbiol20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/jbiol20</ArticleId>
            <ArticleId IdType="pmc">PMC551520</ArticleId>
            <ArticleId IdType="pubmed">15720724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Flier LG, Clevers H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu. Rev. Physiol. 2009;71:241–260. doi: 10.1146/annurev.physiol.010908.163145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.physiol.010908.163145</ArticleId>
            <ArticleId IdType="pubmed">18808327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batlle E, et al.  Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell. 2002;111:251–263. doi: 10.1016/S0092-8674(02)01015-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0092-8674(02)01015-2</ArticleId>
            <ArticleId IdType="pubmed">12408869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korinek V, et al.  Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat. Genet. 1998;19:379–383. doi: 10.1038/1270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/1270</ArticleId>
            <ArticleId IdType="pubmed">9697701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imajo M, Miyatake K, Iimura A, Miyamoto A, Nishida E. A molecular mechanism that links Hippo signalling to the inhibition of Wnt/β-catenin signalling. Embo J. 2012;31:1109–1122. doi: 10.1038/emboj.2011.487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/emboj.2011.487</ArticleId>
            <ArticleId IdType="pmc">PMC3297994</ArticleId>
            <ArticleId IdType="pubmed">22234184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varelas X, et al.  The Hippo pathway regulates Wnt/beta-catenin signaling. Dev. Cell. 2010;18:579–591. doi: 10.1016/j.devcel.2010.03.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2010.03.007</ArticleId>
            <ArticleId IdType="pubmed">20412773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenbluh J, et al.  β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012;151:1457–1473. doi: 10.1016/j.cell.2012.11.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.11.026</ArticleId>
            <ArticleId IdType="pmc">PMC3530160</ArticleId>
            <ArticleId IdType="pubmed">23245941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heallen T, et al.  Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science. 2011;332:458–461. doi: 10.1126/science.1199010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1199010</ArticleId>
            <ArticleId IdType="pmc">PMC3133743</ArticleId>
            <ArticleId IdType="pubmed">21512031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konsavage WM, Jr., Kyler SL, Rennoll SA, Jin G, Yochum GS. Wnt/β-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J. Biol. Chem. 2012;287:11730–11739. doi: 10.1074/jbc.M111.327767.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M111.327767</ArticleId>
            <ArticleId IdType="pmc">PMC3320921</ArticleId>
            <ArticleId IdType="pubmed">22337891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azzolin L, et al.  Role of TAZ as mediator of Wnt signaling. Cell. 2012;151:1443–1456. doi: 10.1016/j.cell.2012.11.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.11.027</ArticleId>
            <ArticleId IdType="pubmed">23245942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137:216–233. doi: 10.1016/j.cell.2009.03.045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2009.03.045</ArticleId>
            <ArticleId IdType="pmc">PMC2827930</ArticleId>
            <ArticleId IdType="pubmed">19379690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bray SJ. Notch signalling: a simple pathway becomes complex. Nat. Rev. Mol. Cell Biol. 2006;7:678–689. doi: 10.1038/nrm2009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2009</ArticleId>
            <ArticleId IdType="pubmed">16921404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Camargo FD, et al.  YAP1 increases organ size and expands undifferentiated progenitor cells. Curr. Biol. 2007;17:2054–2060. doi: 10.1016/j.cub.2007.10.039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2007.10.039</ArticleId>
            <ArticleId IdType="pubmed">17980593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 2009;1:a001651. doi: 10.1101/cshperspect.a001651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a001651</ArticleId>
            <ArticleId IdType="pmc">PMC2882124</ArticleId>
            <ArticleId IdType="pubmed">20457564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun SC. The non-canonical NF-κB pathway in immunity and inflammation. Nat. Rev. Immunol. 2017;17:545–558. doi: 10.1038/nri.2017.52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri.2017.52</ArticleId>
            <ArticleId IdType="pmc">PMC5753586</ArticleId>
            <ArticleId IdType="pubmed">28580957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 2000;18:621–663. doi: 10.1146/annurev.immunol.18.1.621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.immunol.18.1.621</ArticleId>
            <ArticleId IdType="pubmed">10837071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu. Rev. Immunol. 2009;27:693–733. doi: 10.1146/annurev.immunol.021908.132641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.immunol.021908.132641</ArticleId>
            <ArticleId IdType="pubmed">19302050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng Y, et al.  Reciprocal inhibition of YAP/TAZ and NF-κB regulates osteoarthritic cartilage degradation. Nat. Commun. 2018;9:4564. doi: 10.1038/s41467-018-07022-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-07022-2</ArticleId>
            <ArticleId IdType="pmc">PMC6212432</ArticleId>
            <ArticleId IdType="pubmed">30385786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv Y, et al.  YAP controls endothelial activation and vascular inflammation through TRAF6. Circ. Res. 2018;123:43–56. doi: 10.1161/CIRCRESAHA.118.313143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCRESAHA.118.313143</ArticleId>
            <ArticleId IdType="pmc">PMC6014930</ArticleId>
            <ArticleId IdType="pubmed">29794022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q, et al.  REGγ controls Hippo signaling and reciprocal NF-κB-YAP regulation to promote colon cancer. Clin. Cancer Res. 2018;24:2015–2025. doi: 10.1158/1078-0432.CCR-17-2986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-2986</ArticleId>
            <ArticleId IdType="pubmed">29437787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y, et al.  Emerging roles of Hippo signaling in inflammation and YAP-driven tumor immunity. Cancer Lett. 2018;426:73–79. doi: 10.1016/j.canlet.2018.04.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2018.04.004</ArticleId>
            <ArticleId IdType="pubmed">29654891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454:428–435. doi: 10.1038/nature07201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature07201</ArticleId>
            <ArticleId IdType="pubmed">18650913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat. Immunol. 2011;12:715–723. doi: 10.1038/ni.2060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2060</ArticleId>
            <ArticleId IdType="pubmed">21772280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu B, et al.  Toll receptor-mediated hippo signaling controls innate immunity in drosophila. Cell. 2016;164:406–419. doi: 10.1016/j.cell.2015.12.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2015.12.029</ArticleId>
            <ArticleId IdType="pmc">PMC4733248</ArticleId>
            <ArticleId IdType="pubmed">26824654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q, et al.  Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) mediate cell density-dependent proinflammatory responses. J. Biol. Chem. 2018;293:18071–18085. doi: 10.1074/jbc.RA118.004251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.RA118.004251</ArticleId>
            <ArticleId IdType="pmc">PMC6254335</ArticleId>
            <ArticleId IdType="pubmed">30315101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LaCanna R, et al.  Yap/Taz regulate alveolar regeneration and resolution of lung inflammation. J. Clin. Invest. 2019;129:2107–2122. doi: 10.1172/JCI125014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI125014</ArticleId>
            <ArticleId IdType="pmc">PMC6486331</ArticleId>
            <ArticleId IdType="pubmed">30985294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hagenbeek TJ, et al.  The Hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors. Sci. Signal. 2018;11:eaaj1757. doi: 10.1126/scisignal.aaj1757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.aaj1757</ArticleId>
            <ArticleId IdType="pubmed">30206136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye X, Ong N, An H, Zheng Y. The emerging roles of NDR1/2 in infection and inflammation. Front. Immunol. 2020;11:534. doi: 10.3389/fimmu.2020.00534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.00534</ArticleId>
            <ArticleId IdType="pmc">PMC7105721</ArticleId>
            <ArticleId IdType="pubmed">32265942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song H, Wang M, Xin T. Mst1 contributes to nasal epithelium inflammation via augmenting oxidative stress and mitochondrial dysfunction in a manner dependent on Nrf2 inhibition. J. Cell Physiol. 2019;234:23774–23784. doi: 10.1002/jcp.28945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.28945</ArticleId>
            <ArticleId IdType="pubmed">31165471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garbers C, et al.  Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev. 2012;23:85–97. doi: 10.1016/j.cytogfr.2012.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cytogfr.2012.04.001</ArticleId>
            <ArticleId IdType="pubmed">22595692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moroishi T, et al.  The Hippo pathway kinases LATS1/2 suppress cancer immunity. Cell. 2016;167:1525–1539.e1517. doi: 10.1016/j.cell.2016.11.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2016.11.005</ArticleId>
            <ArticleId IdType="pmc">PMC5512418</ArticleId>
            <ArticleId IdType="pubmed">27912060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang F, et al.  The kinases NDR1/2 act downstream of the Hippo homolog MST1 to mediate both egress of thymocytes from the thymus and lymphocyte motility. Sci. Signal. 2015;8:ra100. doi: 10.1126/scisignal.aab2425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.aab2425</ArticleId>
            <ArticleId IdType="pubmed">26443704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, et al.  Mammalian sterile 20-like kinase 1 (Mst1) enhances the stability of forkhead box P3 (Foxp3) and the function of regulatory T cells by modulating Foxp3 acetylation. J. Biol. Chem. 2015;290:30762–30770. doi: 10.1074/jbc.M115.668442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M115.668442</ArticleId>
            <ArticleId IdType="pmc">PMC4692206</ArticleId>
            <ArticleId IdType="pubmed">26538561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du X, et al.  Mst1/Mst2 regulate development and function of regulatory T cells through modulation of Foxo1/Foxo3 stability in autoimmune disease. J. Immunol. 2014;192:1525–1535. doi: 10.4049/jimmunol.1301060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1301060</ArticleId>
            <ArticleId IdType="pubmed">24453252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nehme NT, et al.  MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. Blood. 2012;119:3458–3468. doi: 10.1182/blood-2011-09-378364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2011-09-378364</ArticleId>
            <ArticleId IdType="pmc">PMC3824282</ArticleId>
            <ArticleId IdType="pubmed">22174160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdollahpour H, et al.  The phenotype of human STK4 deficiency. Blood. 2012;119:3450–3457. doi: 10.1182/blood-2011-09-378158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2011-09-378158</ArticleId>
            <ArticleId IdType="pmc">PMC3325036</ArticleId>
            <ArticleId IdType="pubmed">22294732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng J, et al.  The transcriptional coactivator TAZ regulates reciprocal differentiation of T(H)17 cells and T(reg) cells. Nat. Immunol. 2017;18:800–812. doi: 10.1038/ni.3748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.3748</ArticleId>
            <ArticleId IdType="pubmed">28504697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun. Rev. 2014;13:3–10. doi: 10.1016/j.autrev.2013.06.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2013.06.004</ArticleId>
            <ArticleId IdType="pubmed">23774107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou L, et al.  IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 2007;8:967–974. doi: 10.1038/ni1488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni1488</ArticleId>
            <ArticleId IdType="pubmed">17581537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujino S, et al.  Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52:65–70. doi: 10.1136/gut.52.1.65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.52.1.65</ArticleId>
            <ArticleId IdType="pmc">PMC1773503</ArticleId>
            <ArticleId IdType="pubmed">12477762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rovedatti L, et al.  Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 2009;58:1629–1636. doi: 10.1136/gut.2009.182170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.2009.182170</ArticleId>
            <ArticleId IdType="pubmed">19740775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fantini MC, et al.  Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut. 2006;55:671–680. doi: 10.1136/gut.2005.072801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.2005.072801</ArticleId>
            <ArticleId IdType="pmc">PMC1856126</ArticleId>
            <ArticleId IdType="pubmed">16162681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh B, et al.  Control of intestinal inflammation by regulatory T cells. Immunol. Rev. 2001;182:190–200. doi: 10.1034/j.1600-065X.2001.1820115.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1034/j.1600-065X.2001.1820115.x</ArticleId>
            <ArticleId IdType="pubmed">11722634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat. Rev. Immunol. 2011;11:750–761. doi: 10.1038/nri3088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3088</ArticleId>
            <ArticleId IdType="pubmed">22025054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kühl AA, Erben U, Kredel LI, Siegmund B. Diversity of intestinal macrophages in inflammatory bowel diseases. Front. Immunol. 2015;6:613. doi: 10.3389/fimmu.2015.00613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2015.00613</ArticleId>
            <ArticleId IdType="pmc">PMC4670857</ArticleId>
            <ArticleId IdType="pubmed">26697009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou X, et al.  YAP aggravates inflammatory bowel disease by regulating M1/M2 macrophage polarization and gut microbial homeostasis. Cell Rep. 2019;27:1176–1189.e1175. doi: 10.1016/j.celrep.2019.03.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2019.03.028</ArticleId>
            <ArticleId IdType="pubmed">31018132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gehart H, Clevers H. Tales from the crypt: new insights into intestinal stem cells. Nat. Rev. Gastroenterol. Hepatol. 2019;16:19–34. doi: 10.1038/s41575-018-0081-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41575-018-0081-y</ArticleId>
            <ArticleId IdType="pubmed">30429586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crosnier C, Stamataki D, Lewis J. Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. Nat. Rev. Genet. 2006;7:349–359. doi: 10.1038/nrg1840.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrg1840</ArticleId>
            <ArticleId IdType="pubmed">16619050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato T, et al.  Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature. 2011;469:415–418. doi: 10.1038/nature09637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature09637</ArticleId>
            <ArticleId IdType="pmc">PMC3547360</ArticleId>
            <ArticleId IdType="pubmed">21113151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasaki N, et al.  Reg4+ deep crypt secretory cells function as epithelial niche for Lgr5+ stem cells in colon. Proc. Natl Acad. Sci. USA. 2016;113:E5399–E5407. doi: 10.1073/pnas.1607327113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1607327113</ArticleId>
            <ArticleId IdType="pmc">PMC5027439</ArticleId>
            <ArticleId IdType="pubmed">27573849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barry ER, et al.  Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature. 2013;493:106–110. doi: 10.1038/nature11693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11693</ArticleId>
            <ArticleId IdType="pmc">PMC3536889</ArticleId>
            <ArticleId IdType="pubmed">23178811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imajo M, Ebisuya M, Nishida E. Dual role of YAP and TAZ in renewal of the intestinal epithelium. Nat. Cell Biol. 2015;17:7–19. doi: 10.1038/ncb3084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3084</ArticleId>
            <ArticleId IdType="pubmed">25531778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun S, Irvine KD. Cellular organization and cytoskeletal regulation of the hippo signaling network. Trends Cell Biol. 2016;26:694–704. doi: 10.1016/j.tcb.2016.05.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2016.05.003</ArticleId>
            <ArticleId IdType="pmc">PMC4993636</ArticleId>
            <ArticleId IdType="pubmed">27268910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulzke JD, et al.  Epithelial tight junctions in intestinal inflammation. Ann. N. Y. Acad. Sci. 2009;1165:294–300. doi: 10.1111/j.1749-6632.2009.04062.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.2009.04062.x</ArticleId>
            <ArticleId IdType="pubmed">19538319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim NG, Koh E, Chen X, Gumbiner BM. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc. Natl Acad. Sci. USA. 2011;108:11930–11935. doi: 10.1073/pnas.1103345108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1103345108</ArticleId>
            <ArticleId IdType="pmc">PMC3141988</ArticleId>
            <ArticleId IdType="pubmed">21730131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, Qin F, Deng X, Avruch J, Zhou D. Hippo pathway in intestinal homeostasis and tumorigenesis. Protein Cell. 2012;3:305–310. doi: 10.1007/s13238-012-2913-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13238-012-2913-9</ArticleId>
            <ArticleId IdType="pmc">PMC4875478</ArticleId>
            <ArticleId IdType="pubmed">22492181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat. Rev. Gastroenterol. Hepatol. 2015;12:205–217. doi: 10.1038/nrgastro.2015.34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrgastro.2015.34</ArticleId>
            <ArticleId IdType="pubmed">25732745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin Y, et al.  Chemerin aggravates DSS-induced colitis by suppressing M2 macrophage polarization. Cell. Mol. Immunol. 2014;11:355–366. doi: 10.1038/cmi.2014.15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cmi.2014.15</ArticleId>
            <ArticleId IdType="pmc">PMC4085517</ArticleId>
            <ArticleId IdType="pubmed">24727542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramos GP, Papadakis KA. Mechanisms of disease: inflammatory bowel diseases. Mayo Clin. Proc. 2019;94:155–165. doi: 10.1016/j.mayocp.2018.09.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mayocp.2018.09.013</ArticleId>
            <ArticleId IdType="pmc">PMC6386158</ArticleId>
            <ArticleId IdType="pubmed">30611442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perse M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. J. Biomed. Biotechnol. 2012;2012:718617. doi: 10.1155/2012/718617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2012/718617</ArticleId>
            <ArticleId IdType="pmc">PMC3361365</ArticleId>
            <ArticleId IdType="pubmed">22665990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology. 1995;109:1344–1367. doi: 10.1016/0016-5085(95)90599-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0016-5085(95)90599-5</ArticleId>
            <ArticleId IdType="pubmed">7557106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neurath M, Fuss I, Strober W. TNBS-colitis. Int. Rev. Immunol. 2000;19:51–62. doi: 10.3109/08830180009048389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/08830180009048389</ArticleId>
            <ArticleId IdType="pubmed">10723677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okayasu I, et al.  A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990;98:694–702. doi: 10.1016/0016-5085(90)90290-H.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0016-5085(90)90290-H</ArticleId>
            <ArticleId IdType="pubmed">1688816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farooq SM, et al.  Therapeutic effect of blocking CXCR2 on neutrophil recruitment and dextran sodium sulfate-induced colitis. J. Pharmacol. Exp. Ther. 2009;329:123–129. doi: 10.1124/jpet.108.145862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/jpet.108.145862</ArticleId>
            <ArticleId IdType="pubmed">19131582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berndt BE, Zhang M, Chen GH, Huffnagle GB, Kao JY. The role of dendritic cells in the development of acute dextran sulfate sodium colitis. J. Immunol. 2007;179:6255–6262. doi: 10.4049/jimmunol.179.9.6255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.179.9.6255</ArticleId>
            <ArticleId IdType="pubmed">17947701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antoniou E, et al.  The TNBS-induced colitis animal model: An overview. Ann. Med. Surg. (Lond.) 2016;11:9–15. doi: 10.1016/j.amsu.2016.07.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amsu.2016.07.019</ArticleId>
            <ArticleId IdType="pmc">PMC5021709</ArticleId>
            <ArticleId IdType="pubmed">27656280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizoguchi A. Animal models of inflammatory bowel disease. Prog. Mol. Biol. Transl. Sci. 2012;105:263–320. doi: 10.1016/B978-0-12-394596-9.00009-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/B978-0-12-394596-9.00009-3</ArticleId>
            <ArticleId IdType="pubmed">22137435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris GP, et al.  Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989;96:795–803. doi: 10.1016/0016-5085(89)90904-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0016-5085(89)90904-9</ArticleId>
            <ArticleId IdType="pubmed">2914642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurashima Y, Kiyono H. Mucosal ecological network of epithelium and immune cells for gut homeostasis and tissue healing. Annu. Rev. Immunol. 2017;35:119–147. doi: 10.1146/annurev-immunol-051116-052424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-immunol-051116-052424</ArticleId>
            <ArticleId IdType="pubmed">28125357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut. 2013;62:1653–1664. doi: 10.1136/gutjnl-2012-303955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2012-303955</ArticleId>
            <ArticleId IdType="pubmed">24104886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? Nat. Rev. Gastroenterol. Hepatol. 2017;14:9–21. doi: 10.1038/nrgastro.2016.169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrgastro.2016.169</ArticleId>
            <ArticleId IdType="pmc">PMC5554468</ArticleId>
            <ArticleId IdType="pubmed">27848962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61:1619–1635. doi: 10.1136/gutjnl-2012-302830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2012-302830</ArticleId>
            <ArticleId IdType="pubmed">22842618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okamoto R, Watanabe M. Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J. Gastroenterol. 2016;51:11–21. doi: 10.1007/s00535-015-1098-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-015-1098-4</ArticleId>
            <ArticleId IdType="pubmed">26138071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azzolin L, et al.  YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell. 2014;158:157–170. doi: 10.1016/j.cell.2014.06.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2014.06.013</ArticleId>
            <ArticleId IdType="pubmed">24976009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yui S, et al.  YAP/TAZ-dependent reprogramming of colonic epithelium links ECM remodeling to tissue regeneration. Cell Stem Cell. 2018;22:35–49.e37. doi: 10.1016/j.stem.2017.11.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stem.2017.11.001</ArticleId>
            <ArticleId IdType="pmc">PMC5766831</ArticleId>
            <ArticleId IdType="pubmed">29249464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahoney JE, Mori M, Szymaniak AD, Varelas X, Cardoso WV. The hippo pathway effector Yap controls patterning and differentiation of airway epithelial progenitors. Dev. Cell. 2014;30:137–150. doi: 10.1016/j.devcel.2014.06.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2014.06.003</ArticleId>
            <ArticleId IdType="pmc">PMC6331061</ArticleId>
            <ArticleId IdType="pubmed">25043473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gregorieff A, Liu Y, Inanlou MR, Khomchuk Y, Wrana JL. Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer. Nature. 2015;526:715–718. doi: 10.1038/nature15382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature15382</ArticleId>
            <ArticleId IdType="pubmed">26503053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarriault S, et al.  Signalling downstream of activated mammalian Notch. Nature. 1995;377:355–358. doi: 10.1038/377355a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/377355a0</ArticleId>
            <ArticleId IdType="pubmed">7566092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeon MK, Klaus C, Kaemmerer E, Gassler N. Intestinal barrier: Molecular pathways and modifiers. World J. Gastrointest. Pathophysiol. 2013;4:94–99. doi: 10.4291/wjgp.v4.i4.94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4291/wjgp.v4.i4.94</ArticleId>
            <ArticleId IdType="pmc">PMC3829455</ArticleId>
            <ArticleId IdType="pubmed">24244877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okamoto R, et al.  Requirement of Notch activation during regeneration of the intestinal epithelia. Am. J. Physiol. Gastrointest. Liver Physiol. 2009;296:G23–G35. doi: 10.1152/ajpgi.90225.2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpgi.90225.2008</ArticleId>
            <ArticleId IdType="pubmed">19023031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sancho R, Cremona CA, Behrens A. Stem cell and progenitor fate in the mammalian intestine: Notch and lateral inhibition in homeostasis and disease. EMBO Rep. 2015;16:571–581. doi: 10.15252/embr.201540188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embr.201540188</ArticleId>
            <ArticleId IdType="pmc">PMC4428041</ArticleId>
            <ArticleId IdType="pubmed">25855643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Es JH, et al.  Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435:959–963. doi: 10.1038/nature03659.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature03659</ArticleId>
            <ArticleId IdType="pubmed">15959515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grivennikov S, et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15:103–113. doi: 10.1016/j.ccr.2009.01.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2009.01.001</ArticleId>
            <ArticleId IdType="pmc">PMC2667107</ArticleId>
            <ArticleId IdType="pubmed">19185845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ernst M, Thiem S, Nguyen PM, Eissmann M, Putoczki TL. Epithelial gp130/Stat3 functions: an intestinal signaling node in health and disease. Semin. Immunol. 2014;26:29–37. doi: 10.1016/j.smim.2013.12.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.smim.2013.12.006</ArticleId>
            <ArticleId IdType="pubmed">24434062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishida A, et al.  Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin. J. Gastroenterol. 2018;11:1–10. doi: 10.1007/s12328-017-0813-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12328-017-0813-5</ArticleId>
            <ArticleId IdType="pubmed">29285689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? Nat. Rev. Gastroenterol. Hepatol. 2017;14:573–584. doi: 10.1038/nrgastro.2017.88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrgastro.2017.88</ArticleId>
            <ArticleId IdType="pmc">PMC5880536</ArticleId>
            <ArticleId IdType="pubmed">28743984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mosca A, Leclerc M, Hugot JP. Gut microbiota diversity and human diseases: should we reintroduce key predators in our ecosystem? Front. Microbiol. 2016;7:455. doi: 10.3389/fmicb.2016.00455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2016.00455</ArticleId>
            <ArticleId IdType="pmc">PMC4815357</ArticleId>
            <ArticleId IdType="pubmed">27065999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ott SJ, et al.  Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53:685–693. doi: 10.1136/gut.2003.025403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.2003.025403</ArticleId>
            <ArticleId IdType="pmc">PMC1774050</ArticleId>
            <ArticleId IdType="pubmed">15082587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manichanh C, et al.  Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2006;55:205–211. doi: 10.1136/gut.2005.073817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.2005.073817</ArticleId>
            <ArticleId IdType="pmc">PMC1856500</ArticleId>
            <ArticleId IdType="pubmed">16188921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franzosa EA, et al.  Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat. Microbiol. 2019;4:293–305. doi: 10.1038/s41564-018-0306-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41564-018-0306-4</ArticleId>
            <ArticleId IdType="pmc">PMC6342642</ArticleId>
            <ArticleId IdType="pubmed">30531976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hold GL, et al.  Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J. Gastroenterol. 2014;20:1192–1210. doi: 10.3748/wjg.v20.i5.1192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v20.i5.1192</ArticleId>
            <ArticleId IdType="pmc">PMC3921503</ArticleId>
            <ArticleId IdType="pubmed">24574795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, et al.  Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J. Clin. Microbiol. 2014;52:398–406. doi: 10.1128/JCM.01500-13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.01500-13</ArticleId>
            <ArticleId IdType="pmc">PMC3911339</ArticleId>
            <ArticleId IdType="pubmed">24478468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin. Immunopathol. 2015;37:47–55. doi: 10.1007/s00281-014-0454-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00281-014-0454-4</ArticleId>
            <ArticleId IdType="pmc">PMC4281375</ArticleId>
            <ArticleId IdType="pubmed">25420450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sajib S, Zahra FT, Lionakis MS, German NA, Mikelis CM. Mechanisms of angiogenesis in microbe-regulated inflammatory and neoplastic conditions. Angiogenesis. 2018;21:1–14. doi: 10.1007/s10456-017-9583-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10456-017-9583-4</ArticleId>
            <ArticleId IdType="pubmed">29110215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danese S, et al.  Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut. 2007;56:855–862. doi: 10.1136/gut.2006.114314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.2006.114314</ArticleId>
            <ArticleId IdType="pmc">PMC1954843</ArticleId>
            <ArticleId IdType="pubmed">17170016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danese S, et al.  Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006;130:2060–2073. doi: 10.1053/j.gastro.2006.03.054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2006.03.054</ArticleId>
            <ArticleId IdType="pubmed">16762629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chidlow JH, Jr., et al.  Differential angiogenic regulation of experimental colitis. Am. J. Pathol. 2006;169:2014–2030. doi: 10.2353/ajpath.2006.051021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2353/ajpath.2006.051021</ArticleId>
            <ArticleId IdType="pmc">PMC1762465</ArticleId>
            <ArticleId IdType="pubmed">17148665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hatoum OA, Binion DG. The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. Inflamm. Bowel Dis. 2005;11:304–313. doi: 10.1097/01.MIB.0000160772.78951.61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.MIB.0000160772.78951.61</ArticleId>
            <ArticleId IdType="pubmed">15735437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boopathy GTK, Hong W. Role of Hippo pathway-YAP/TAZ signaling in angiogenesis. Front. Cell Dev. Biol. 2019;7:49. doi: 10.3389/fcell.2019.00049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2019.00049</ArticleId>
            <ArticleId IdType="pmc">PMC6468149</ArticleId>
            <ArticleId IdType="pubmed">31024911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marti P, et al.  YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors. Hepatology. 2015;62:1497–1510. doi: 10.1002/hep.27992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.27992</ArticleId>
            <ArticleId IdType="pubmed">26173433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi HJ, et al.  Yes-associated protein regulates endothelial cell contact-mediated expression of angiopoietin-2. Nat. Commun. 2015;6:6943. doi: 10.1038/ncomms7943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms7943</ArticleId>
            <ArticleId IdType="pubmed">25962877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan L, et al.  Palmitic acid dysregulates the Hippo-YAP pathway and inhibits angiogenesis by inducing mitochondrial damage and activating the cytosolic DNA sensor cGAS-STING-IRF3 signaling mechanism. J. Biol. Chem. 2017;292:15002–15015. doi: 10.1074/jbc.M117.804005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M117.804005</ArticleId>
            <ArticleId IdType="pmc">PMC5592676</ArticleId>
            <ArticleId IdType="pubmed">28698384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, et al.  YAP/TAZ regulates sprouting angiogenesis and vascular barrier maturation. J. Clin. Invest. 2017;127:3441–3461. doi: 10.1172/JCI93825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI93825</ArticleId>
            <ArticleId IdType="pmc">PMC5669570</ArticleId>
            <ArticleId IdType="pubmed">28805663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azad T, Ghahremani M, Yang X. The role of YAP and TAZ in angiogenesis and vascular mimicry. Cells. 2019;8:407. doi: 10.3390/cells8050407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8050407</ArticleId>
            <ArticleId IdType="pmc">PMC6562567</ArticleId>
            <ArticleId IdType="pubmed">31052445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, et al.  YAP/TAZ orchestrate VEGF signaling during developmental angiogenesis. Dev. Cell. 2017;42:462–478.e467. doi: 10.1016/j.devcel.2017.08.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2017.08.002</ArticleId>
            <ArticleId IdType="pubmed">28867486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azad T, et al.  A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis. Nat. Commun. 2018;9:1061. doi: 10.1038/s41467-018-03278-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-03278-w</ArticleId>
            <ArticleId IdType="pmc">PMC5849716</ArticleId>
            <ArticleId IdType="pubmed">29535383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park JA, Kwon YG. Hippo-YAP/TAZ signaling in angiogenesis. BMB Rep. 2018;51:157–162. doi: 10.5483/BMBRep.2018.51.3.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5483/BMBRep.2018.51.3.016</ArticleId>
            <ArticleId IdType="pmc">PMC5882223</ArticleId>
            <ArticleId IdType="pubmed">29366443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi HJ, Kwon YG. Roles of YAP in mediating endothelial cell junctional stability and vascular remodeling. BMB Rep. 2015;48:429–430. doi: 10.5483/BMBRep.2015.48.8.146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5483/BMBRep.2015.48.8.146</ArticleId>
            <ArticleId IdType="pmc">PMC4576949</ArticleId>
            <ArticleId IdType="pubmed">26169195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He J, et al.  Yes-associated protein promotes angiogenesis via signal transducer and activator of transcription 3 in endothelial cells. Circ. Res. 2018;122:591–605. doi: 10.1161/CIRCRESAHA.117.311950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCRESAHA.117.311950</ArticleId>
            <ArticleId IdType="pubmed">29298775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chidlow JH, Jr., Shukla D, Grisham MB, Kevil CG. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am. J. Physiol. Gastrointest. Liver Physiol. 2007;293:G5–g18. doi: 10.1152/ajpgi.00107.2007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpgi.00107.2007</ArticleId>
            <ArticleId IdType="pubmed">17463183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi HJ, Kim NE, Kim BM, Seo M, Heo JH. TNF-α-induced YAP/TAZ activity mediates leukocyte-endothelial adhesion by regulating VCAM1 expression in endothelial cells. Int. J. Mol. Sci. 2018;19:3428. doi: 10.3390/ijms19113428.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms19113428</ArticleId>
            <ArticleId IdType="pmc">PMC6274800</ArticleId>
            <ArticleId IdType="pubmed">30388809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sivaraj KK, et al.  YAP1 and TAZ negatively control bone angiogenesis by limiting hypoxia-inducible factor signaling in endothelial cells. Elife. 2020;9:e50770. doi: 10.7554/eLife.50770.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.50770</ArticleId>
            <ArticleId IdType="pmc">PMC6970532</ArticleId>
            <ArticleId IdType="pubmed">31958058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He J, et al.  The role of Hippo/yes-associated protein signalling in vascular remodelling associated with cardiovascular disease. Br. J. Pharm. 2018;175:1354–1361. doi: 10.1111/bph.13806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.13806</ArticleId>
            <ArticleId IdType="pmc">PMC5866970</ArticleId>
            <ArticleId IdType="pubmed">28369744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandor Z, Deng XM, Khomenko T, Tarnawski AS, Szabo S. Altered angiogenic balance in ulcerative colitis: a key to impaired healing? Biochem. Biophys. Res. Commun. 2006;350:147–150. doi: 10.1016/j.bbrc.2006.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2006.09.021</ArticleId>
            <ArticleId IdType="pubmed">17011522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stokkers PC, Hommes DW. New cytokine therapeutics for inflammatory bowel disease. Cytokine. 2004;28:167–173. doi: 10.1016/j.cyto.2004.07.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2004.07.012</ArticleId>
            <ArticleId IdType="pubmed">15588691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scaldaferri F, et al.  VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology. 2009;136:585–595.e585. doi: 10.1053/j.gastro.2008.09.064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2008.09.064</ArticleId>
            <ArticleId IdType="pubmed">19013462</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
